IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
about
Immunotherapeutic potential of extracellular vesiclesImmunostimulatory Activity of the Cytokine-Based Biologic, IRX-2, on Human Papillomavirus-Exposed Langerhans Cells.Tumor-Derived Exosomes and Their Role in Tumor-Induced Immune SuppressionTumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes.Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg).Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model.Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets.Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma.Exosomes and tumor-mediated immune suppression.The immune signature of CD8(+)CCR7(+) T cells in the peripheral circulation associates with disease recurrence in patients with HNSCC.IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes)Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy.Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.Exosomes: immune properties and potential clinical implementations.PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.The clinical implications of antitumor immunity in head and neck cancer.The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.Clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers.Immunotherapy for head and neck cancer: the future of treatment?Tumor-Derived Exosomes and Their Role in Cancer Progression.Exosomes carrying immunoinhibitory proteins and their role in cancer.Mechanisms of T-cell protection from death by IRX-2: a new immunotherapeutic.Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.Therapeutic vaccines for high-risk HPV-associated diseases.The effect of tumor-derived exosomes on immune regulation and cancer immunotherapy.Exosomes in Cancer: Another Mechanism of Tumor-Induced Immune Suppression.Exosome-Based Cell-Cell Communication in the Tumor Microenvironment.Exosomes and Immune Response in Cancer: Friends or Foes?Hypoxia affects dendritic cell survival: role of the hypoxia-inducible factor-1α and lipopolysaccharide.Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen.IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.
P2860
Q27023323-98F5D331-461C-4E74-833F-15D40AF31E4CQ27307719-FDEFF365-D7D1-48F2-A659-10FD0AAF7C36Q28076769-00EC868B-A843-4B27-8329-141554D9BC06Q30541774-10780362-7A90-48F9-9B1B-6E73A4DDB0CDQ33641504-9F083484-0A5D-45F9-997B-82D865A9EA22Q33772810-BC784787-259B-4E8E-A7B6-214968A45FACQ35714195-A19EC882-B229-49C6-B420-3D027003EB75Q36542190-96069074-20E3-41E4-BDFA-F4E7349014D8Q36670900-883A4B7C-21BC-4637-83D0-1C0D0426976DQ36737920-6CDA7B89-B929-43D7-9C01-2F02C552434CQ37002948-C31A0825-25A4-4F56-8FCD-AD9E33C5F632Q37040481-81587927-1C18-4ACF-8AB2-8D778B580EC1Q37040486-AFDF4809-71C5-45BA-8171-98D17E0C890DQ37259621-4E8BF1F8-B415-49ED-BCF3-50D28483CCCBQ37507018-3858C35E-96F7-4D75-B17A-1073E7C8272DQ37634052-FDEEBD19-9BA6-44B0-BCB9-7F15DCE42B28Q37822692-98ED9DBD-53C6-43A7-9395-D469A2054795Q37951937-8448A06A-D21A-468E-91D8-0B18EB904088Q37970005-CF737816-3530-460F-B50D-CD71062D85FBQ38161874-E560AE0D-38BD-4B93-ABCF-83153CE02189Q38209889-31DDF6E1-9C01-4338-B6BE-1EB01F4EB502Q38736238-83E662ED-C11C-4715-AEBA-326B99999C86Q38818439-7AAEACAF-06E6-4628-AC1D-2CEA15165A89Q39215663-9634FFD2-D60A-466A-9DF2-F9F9FF712BCDQ39616709-97344F7B-9522-4D13-B275-AA320321CFABQ41006936-A8287622-11A4-4BB6-9BD6-CE1FE51FC973Q47255618-3831A937-4BD7-4F46-A2CE-61EB351CA0D9Q47337961-BEFD1119-C5DE-4C4C-89B9-34C3396CB273Q49592892-4C45D757-95DD-4B78-B79D-E6E8A4BC071FQ52363481-39C786AD-A4E3-44CA-9D59-08F3FD387218Q52562641-F2EAD9E4-CAC2-4696-8D90-843DE5AA05A5Q53257878-13F5DD8B-6DC3-4708-8CA5-CADAC3EAF2EAQ55293126-17599AEB-3847-427A-8C71-6BB80A07135CQ55515909-AD5B468F-9144-4151-895D-B83B01BB0812
P2860
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
@en
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
@nl
type
label
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
@en
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
@nl
prefLabel
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
@en
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
@nl
P2093
P2860
P356
P1476
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.
@en
P2093
H Brandwein
J W Hadden
K Quadrini
K Signorelli
M Czystowska
M J Szczepanski
T L Whiteside
P2860
P2888
P304
P356
10.1038/CDD.2008.197
P577
2009-01-30T00:00:00Z